BRIAN SAID : "Those looking for an oncology-focused drugmaker with more impressive compounds in development should take a look at GPC Biotech (Nasdaq: GPCB) or Rule Breakers pick Exelixis (Nasdaq: EXEL) instead (OF DNDN --- MY ADDITION). It's time to go to CAPS and rate Dendreon underperform -- at least until the interim IMPACT data comes out."
very DRAMTIC dropp IN PPS over TIME .. IT LOOKS LIKE BOTTOM.. WHAT IS BOOK VALUE? ANY CASH? DEBT?
TIA
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM